PHAL: Net loss persists, but R&D and cleantech advances drive optimism amid tight liquidity

About this update from Pharmalundensis Ab

Net loss widened to -1.45 MSEK with no sales, but successful Phal-501 animal tests and cleantech product development marked operational progress. Rights issue raised 2.53 MSEK; capital remains tight pending further financing. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmalundensis Ab